International Conference on Cell Therapy and Tissue Engineering: Regenerative Medicine – New Developments

International Conference on Cell Therapy and Tissue Engineering:  Regenerative Medicine – New Developments will be held on 8th-9th June 2016 in Tallinn, Estonia.

What is regenerative medicine (RM) and why many consider it a way out of the puzzled present and into the promising future of medicine? RM is a discipline that does nothing else but stimulates human body´s capability to cure and heal itself. Human body has taken care of itself during several thousand years, but in some instances it fails. The aim of RM is to give a helping hand in these instances.
What is already possible today and in the coming future? What is RM capable of doing today and which direction should it take tomorrow? If we have a brilliant idea, to whom should we forward it in order to be successful and where to find an investor? Should legislation regulate the evolution of RM and if yes, in which way? Based on today´s knowledge of RM – what seems as a hope and what as a hype? How should venture capitalists (risk investors) recognize a fruitful idea and distinguish it from a scam?

Who are the broader target groups we expect to see sitting in the auditorium and listen?
1. Medical Clinicians, who want to find new treatment modalities, because today´s conventional methods don´t help their patients enough. Who should they approach with some of their new ideas? Mostly all new ideas be down regulated by the National Drug Administration Committee? How can we spare innovation from the bureaucratic regulations?
2. Researchers, who want to find a more precise focus for their research projects. What regulatory instruments will help them and which will block their activities? Where to find financial investors? Is there a need on the market for their projects (results)?
3. Regulators, who sit among different Ministries and Drug Administration Committees. How strongly should RM be regulated? How decision-making-bureaucracy can favor new inventions of RM?
4. Back-up-forces. How should pharmaceutical companies, IT specialists, venture capitalists etc. behave, when they see a new biotechnological “bubble” getting started? How IT knowledge can be used to protect interests of the patients?

Please register in the following link:
The fees are following:

Until 30th April 2016 159 euros (Student, residents 119 euros);
Until 6th June 2016 199 euros (Student, residents 149 euros);
7th-8th June 2016 259 euros.

Registration fee includes two days of participation, conference materials via internet, coffee breaks and lunches.
Conference will take place at Nordic Hotel Forum in Tallinn (Viru väljak 3, phone 622 2900).